DK1827483T3 - Terapeutiske formuleringer af keratinocyt-vækstfaktor - Google Patents
Terapeutiske formuleringer af keratinocyt-vækstfaktorInfo
- Publication number
- DK1827483T3 DK1827483T3 DK05853972.7T DK05853972T DK1827483T3 DK 1827483 T3 DK1827483 T3 DK 1827483T3 DK 05853972 T DK05853972 T DK 05853972T DK 1827483 T3 DK1827483 T3 DK 1827483T3
- Authority
- DK
- Denmark
- Prior art keywords
- growth factor
- keratinocyte growth
- therapeutic formulations
- formulations
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63621004P | 2004-12-15 | 2004-12-15 | |
| PCT/US2005/045169 WO2006065861A2 (en) | 2004-12-15 | 2005-12-12 | Therapeutic formulations of keratinocyte growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1827483T3 true DK1827483T3 (da) | 2014-10-06 |
Family
ID=36337531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05853972.7T DK1827483T3 (da) | 2004-12-15 | 2005-12-12 | Terapeutiske formuleringer af keratinocyt-vækstfaktor |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8304387B2 (da) |
| EP (1) | EP1827483B1 (da) |
| JP (1) | JP5201992B2 (da) |
| KR (1) | KR101283736B1 (da) |
| CN (1) | CN101084008B (da) |
| AR (1) | AR052339A1 (da) |
| AU (1) | AU2005317166B2 (da) |
| BR (1) | BRPI0519070A2 (da) |
| CA (1) | CA2589889C (da) |
| CR (1) | CR9246A (da) |
| DK (1) | DK1827483T3 (da) |
| EA (1) | EA013369B1 (da) |
| ES (1) | ES2504441T3 (da) |
| HK (1) | HK1115298A1 (da) |
| HR (1) | HRP20140926T1 (da) |
| IL (1) | IL183435A (da) |
| MX (1) | MX2007006822A (da) |
| MY (1) | MY145638A (da) |
| NO (1) | NO20073629L (da) |
| NZ (1) | NZ555503A (da) |
| PL (1) | PL1827483T3 (da) |
| PT (1) | PT1827483E (da) |
| RS (1) | RS53548B1 (da) |
| SI (1) | SI1827483T1 (da) |
| TW (1) | TWI351966B (da) |
| UA (1) | UA88497C2 (da) |
| WO (1) | WO2006065861A2 (da) |
| ZA (1) | ZA200706095B (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1827483E (pt) | 2004-12-15 | 2014-09-25 | Swedish Orphan Biovitrum Ab Publ | Formulações terapêuticas do fator de crescimento de queratinócitos |
| US20090186805A1 (en) * | 2006-07-06 | 2009-07-23 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
| KR100784134B1 (ko) * | 2006-10-09 | 2007-12-12 | 주식회사 대웅 | 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물 |
| CN101780269A (zh) * | 2009-01-21 | 2010-07-21 | 北京三有利科技发展有限公司 | 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用 |
| IT1396020B1 (it) * | 2009-10-16 | 2012-11-09 | Fitologica Srl | Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico. |
| CN102675449B (zh) * | 2011-03-17 | 2016-06-08 | 重庆富进生物医药有限公司 | 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 |
| US20140287995A1 (en) * | 2011-11-02 | 2014-09-25 | The University Of Chicago | Stable pharmaceutical formulations of growth factor peptides |
| CN102379838B (zh) * | 2011-11-02 | 2013-06-12 | 广州舒泰生物技术有限公司 | 一种舒缓静颜化妆品的制备方法及应用 |
| US20150126433A1 (en) * | 2012-04-25 | 2015-05-07 | University Of Cincinnati | Growth factors for the treatment of mycobacterial infection |
| AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
| CN108359634A (zh) * | 2018-02-02 | 2018-08-03 | 江阴司特易生物技术有限公司 | 一种饲养细胞蛋白复合物及其应用 |
| CN109402130A (zh) * | 2018-11-23 | 2019-03-01 | 成都中医药大学附属医院 | 一种重组人角质细胞生长因子-1及其制备方法和用途 |
| CN110339345B (zh) * | 2019-07-30 | 2022-11-29 | 重庆派金生物科技有限公司 | 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用 |
| EP4183796A1 (en) | 2021-11-19 | 2023-05-24 | Enantis s.r.o. | Thermostable fgf10 polypeptide or fragment thereof use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026291B1 (en) | 1989-01-31 | 2006-04-11 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial cell specific growth factor, keratinocyte growth factor (KGF) |
| EP0555205B1 (en) | 1989-01-31 | 2000-11-29 | RUBIN, Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
| ATE227583T1 (de) * | 1991-12-20 | 2002-11-15 | Novo Nordisk As | Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält |
| NZ266622A (en) | 1993-06-29 | 1997-10-24 | Chiron Corp | Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates |
| US7084119B2 (en) | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| EP0804479B1 (en) | 1994-10-13 | 2006-10-11 | Amgen Inc., | Method of treating diabetes mellitus using kgf |
| US6008328A (en) | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
| ES2196088T3 (es) | 1994-10-13 | 2003-12-16 | Amgen Inc | Analogos del factor de crecimiento de los queratinocitos. |
| US6790439B1 (en) * | 1995-06-07 | 2004-09-14 | Zymogenetics, Inc. | Thrombopoietin compositions |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| ATE220689T1 (de) * | 1996-12-06 | 2002-08-15 | Amgen Inc | Verwendung eines kgf-proteinproduktes und eines glp-2 proteinproduktes für die herstellung eines medikamentes |
| US20020012961A1 (en) * | 1999-04-15 | 2002-01-31 | Genentech, Inc. | Fibroblast growth factor- 19 |
| US6238888B1 (en) * | 1997-12-22 | 2001-05-29 | Human Genone Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| JP2003500456A (ja) * | 1999-06-02 | 2003-01-07 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 角質細胞増殖因子−２製剤 |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| PT1827483E (pt) | 2004-12-15 | 2014-09-25 | Swedish Orphan Biovitrum Ab Publ | Formulações terapêuticas do fator de crescimento de queratinócitos |
-
2005
- 2005-12-12 PT PT58539727T patent/PT1827483E/pt unknown
- 2005-12-12 DK DK05853972.7T patent/DK1827483T3/da active
- 2005-12-12 ES ES05853972.7T patent/ES2504441T3/es active Active
- 2005-12-12 JP JP2007546844A patent/JP5201992B2/ja not_active Expired - Fee Related
- 2005-12-12 US US11/302,033 patent/US8304387B2/en active Active
- 2005-12-12 PL PL05853972T patent/PL1827483T3/pl unknown
- 2005-12-12 EA EA200701293A patent/EA013369B1/ru not_active IP Right Cessation
- 2005-12-12 RS RSP20140512 patent/RS53548B1/en unknown
- 2005-12-12 BR BRPI0519070-3A patent/BRPI0519070A2/pt not_active IP Right Cessation
- 2005-12-12 MX MX2007006822A patent/MX2007006822A/es active IP Right Grant
- 2005-12-12 EP EP05853972.7A patent/EP1827483B1/en active Active
- 2005-12-12 KR KR1020077013435A patent/KR101283736B1/ko not_active IP Right Cessation
- 2005-12-12 NZ NZ555503A patent/NZ555503A/en not_active IP Right Cessation
- 2005-12-12 CN CN2005800433149A patent/CN101084008B/zh not_active Expired - Fee Related
- 2005-12-12 AU AU2005317166A patent/AU2005317166B2/en not_active Ceased
- 2005-12-12 UA UAA200707966A patent/UA88497C2/ru unknown
- 2005-12-12 CA CA2589889A patent/CA2589889C/en not_active Expired - Fee Related
- 2005-12-12 WO PCT/US2005/045169 patent/WO2006065861A2/en active Application Filing
- 2005-12-12 SI SI200531886T patent/SI1827483T1/sl unknown
- 2005-12-14 AR ARP050105231A patent/AR052339A1/es unknown
- 2005-12-15 TW TW094144470A patent/TWI351966B/zh not_active IP Right Cessation
- 2005-12-15 MY MYPI20055903A patent/MY145638A/en unknown
-
2007
- 2007-05-27 IL IL183435A patent/IL183435A/en not_active IP Right Cessation
- 2007-07-13 ZA ZA200706095A patent/ZA200706095B/xx unknown
- 2007-07-13 NO NO20073629A patent/NO20073629L/no not_active Application Discontinuation
- 2007-07-13 CR CR9246A patent/CR9246A/es unknown
-
2008
- 2008-05-06 HK HK08105042.9A patent/HK1115298A1/xx not_active IP Right Cessation
-
2014
- 2014-09-26 HR HRP20140926TT patent/HRP20140926T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1827483T3 (da) | Terapeutiske formuleringer af keratinocyt-vækstfaktor | |
| DK1992697T3 (da) | Fremstilling af TNFR-Fc | |
| LTC1761540I2 (lt) | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai | |
| DK1802579T3 (da) | Derivater af 3-arylaminopyridin | |
| DK1763673T3 (da) | Anvendelser af gelformuleringer | |
| DK1778618T3 (da) | Syntese af triethylentetraminer | |
| DK3395338T3 (da) | Hurtigt opløsende formulering af cinacalcet-hcl | |
| DK1812025T3 (da) | Stabiliserede bakteriofagformuleringer | |
| ATE432056T1 (de) | Zervikale zwischenwirbelprothese | |
| DK1653807T3 (da) | Anvendelse af dermale mikroorganer | |
| DK1708992T3 (da) | Sulfonamidderivater til behandling af sygdomme | |
| DK1931315T3 (da) | Depotformuleringer af nalbufin | |
| CY2013035I1 (el) | Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης | |
| DK1639010T3 (da) | Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom | |
| DK1658295T3 (da) | Regioselektiv syntese af CCI-779 | |
| DK1945277T3 (da) | Opretholdelse af desinfektion af medicinsk udstyr | |
| IS8597A (is) | Samsetningar rísedrónats og aðferðir við notkun þess | |
| DK1744781T3 (da) | Behandling af infektionssygdomme | |
| DK1587542T3 (da) | Anvendelse af anti-CD100-antistoffer | |
| CR9144A (es) | Formulaciones de benzoxazoles sustituidos | |
| DK1516540T3 (da) | Anvendelse af vitamin D-forbindelser | |
| NO20043305D0 (no) | Preparation of lodixanol | |
| DK1812002T3 (da) | Behandling af mastitis | |
| MA28846B1 (fr) | Composition biologiquement active | |
| DK2301576T3 (da) | Terapeutisk anvendelse af anti-CS1-antistoffer |